The pharmacological treatment of childhood anxiety disorders

International Review of Psychiatry

Volumn 14, Issue 2, 2002, Pages 135-142

  Walkup, John T ^a   Labellarte, Michael J ^a   Ginsburg, Golda S ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CHLORDIAZEPOXIDE; CLOMIPRAMINE; DIPHENHYDRAMINE; DOXEPIN; FLUVOXAMINE; MEPROBAMATE; METHYLPHENOBARBITAL; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; PHENOBARBITAL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANXIETY NEUROSIS; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; PHOBIA; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE;

EID: 0036062412     PISSN: 09540261     EISSN: None     Source Type: Journal    
DOI: 10.1080/09540260220132653     Document Type: Article

References (112)

1. Cognitive-behavioral group treatment for social phobia in adolescents: A preliminary study
2. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: Pharmacokinetics, tolerability, and efficacy
3. Fears and anxieties
4. Evaluation of cognitive-behavioral group treatments for childhood anxiety disorders
5. Family intervention for childhood anxiety
6. Determining the reliability psychophysiological assessment in childhood anxiety
7. The feasibility and validity of a daily diary for the assessment of anxiety in children
8. Separation anxiety disorder, overanxious disorder, and school refusal
9. School phobia: A therapeutic trial with clomipramine and short term outcome
10. Comparative studies of pharmacotherapy for school refusal
11. Treatment of school refusal: One-year follow-up
12. Imipramine plus cognitive-behavioral therapy in the treatment of school refusal
13. Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders (SCARED): A replication study
14. The screen for child anxiety related emotional disorders (SCARED): Scale construction and psychometric characteristics
15. Fluoxetine for childhood anxiety disorders
16. Treatment of elective mutism with fluoxetine: A double-blind, placebo-controlled study
17. The role of parental anxiety in the treatment of childhood anxiety
18. Review and update: Benzodiazapines in childhood and adolescence
19. Pharmacokinetics of benzodiazapines and psychostimulants in children
20. Drug treatment of anxiety disorders in children
21. The effectiveness of tranquilizing drugs plus supportive psychotherapy in treating behavior disorders of children: A double blind study of eighty outpatients
22. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: A double-blind placebo controlled trial
23. Behavior therapy versus clomipramine for the treatment of OCD in children and adolescents
24. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder - A multicenter trial
25. Structured psychiatric interviews for children and adolescents
26. A double-blind, placebo controlled trial of fluoxetine in children and adolescents with depression
27. The effectiveness of psychotherapy alone and in conjunction with perphenazine or placebo in the treatment of neurotic and hyperkinetic children
28. Open fluoxetine treatment of mixed anxiety disorders in children and adolescents
29. Anxiety and depression in children and adolescents: Negative affectivity or separate constructs?
30. Nefazodone pharmacokinetics in depressed children and adolescents
31. Paroxetine pharmacokinetics in depressed children and adolescents
32. Clomipramine treatment of childhood obsessive-compulsive disorder
33. Cognitive-behavioral treatment of pediatric obsessive-compulsive disorder: An open clinical trial
34. Treatment of childhood depression with antidepressant drugs
35. Specificity in familial aggregation of phobic disorders
36. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: A placebo-controlled clinical trial
37. Family involvement in treating children with phobic and anxiety disorders: A look ahead
38. Controlled imipramine treatment of school phobia
39. School phobia: Diagnostic considerations in light of imipramine effects
40. An observational approach to the assessment of anxiety in young children
41. Cognitive-behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis
42. Cognitive-behavioral and pharmacological treatment for social phobia: A meta-analysis
43. Clonazepam in childhood anxiety disorders
44. Discriminating anxiety an depression in youth: A role for diagnostic criteria
45. Cognitive-behavioral group therapy for social phobia in female adolescents: Results of a pilot study
46. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial
47. Followup of adolescents initially treated for prepubertal-onset major depressive disorder with Imipramine
48. Schedule for affective disorders and schizophrenia for school-aged children - Present and lifetime version (K-SADS-PL): Initial reliability and validity data
49. Treating anxiety disorders in children: Results of a randomized clinical trial
50. Comorbidity in the anxiety disorders of childhood
51. Long-term follow-up of a cognitive-behavioral therapy for anxiety-disordered youths
52. Therapy for youths with anxiety disorders: A second randomized clinical trial
53. Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial
54. Negative affectivity in children and adolescents: Relations between anxiety and depression
55. Imipramine treatment in children with separation anxiety disorder
56. WWG and behavioral affects of drug therapy in children. Chlorpromazine and diphenhydramine
57. The treatment of anxiety disorders in children and adolescents
58. Anxious children in adulthood: A prospective study of adjustment
59. Anxiety disorders in children and their families
60. The Yale Global Tic Severity Scale (YGTSS): Initial testing of a clinical-rated scale of tic severity
61. Pharmacology of selective serotonin reuptake inhibitors in children and adolescents
62. Treatment of obsessive-compulsive disorder With clomipramine and desipramine in children and adolescents: A double-blind crossover comparison
63. Behavioral therapy for children and adolescents with obsessive-compulsive disorder: An open trial with a protocol driven package
64. The multidimensional anxiety scale for children (MASC): Factor structure, reliability, and validity
65. Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial
66. Reductions of anxiety in children facing hospitalization and surgery by use of filmed modeling
67. Anxiety attacks with subsequent agoraphobia
68. Cognitive-behavioral group treatments in childhood anxiety disorders: The role of parental involvement
69. Buspirone treatment of psychiatrically hospitalized prepubertal children with symptoms of anxiety and moderately severe aggression
70. Do childhood anxiety measures measure anxiety?
71. Differential carbon-dioxide sensitivity in childhood anxiety disorders and normal comparison group
72. Anxiety disorders
73. The risk for early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders
74. Clinical Global Impression (CGI) Scale
75. Reliability of the DSM-III-R childhood anxiety disorders using structured interview: Interrater and parent-child agreement
76. Efficacy of psychiatric medications in children and adolescents: A review of controlled studies
77. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: A randomized, controlled, multicenter trial
78. Fluvoxamine for the treatment of anxiety disorders in children and adolescents
79. Building a reasonable bridge in childhood anxiety assessment: A practitioners resource guide
80. Pharmacological treatment of adolescent psychiatric disorders
81. Imipramine in adolescent major depression: Plasma level and clinical response
82. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder
83. Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity
84. Fluoxetine has no marked effect on tic symptoms in patients with Tourette's syndrome: A double blind placebo controlled study
85. Age differences in the reliability of parent and child reports of child anxious symptomatology using a structured interview
86. The Anxiety Disorders Interview Schedule for Children
87. Test-retest reliability of the DSM-III-R anxiety childhood disorders symptoms using the Anxiety Disorders Interview Schedule for Children
88. Clinical issues in treating children with anxiety and phobic disorders
89. Treating anxiety disorders in children with group cognitive behavior therapy: A randomized clinical trial
90. Contingency management, self-control, and education support in the treatment of childhood phobic disorders: A randomized clinical trial
91. The treatment of childhood social phobia: The effectiveness of a social skills training-based, cognitive-behavioral intervention, with and without parental involvement
92. Alprazolam effects in children with anxiety disorders
93. Clinical, cognitive, and neurophysiological effects of alprazolam in children and adolescents with overanxious and avoidant disorders
94. Buspirone therapy of mixed anxiety disorders in childhood and adolescence: A pilot study
95. Pharmacotherapy of attention deficit hyperactivity disorder
96. Pindolol potentiation of paroxetine for generalized social phobia: A double-blind, placebo-controlled, crossover study
97. Behavioral and physiological effects of short-term and long-term administration of clonidine in panic disorder
98. Nefazodone in social phobia
99. Therapy for youths with anxiety disorders: A second randomized clinical trial